ANAB vs. ALBO, RNA, TGTX, INDV, JANX, ACAD, ARVN, BHC, MRVI, and DCPH
Should you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Albireo Pharma (ALBO), Avidity Biosciences (RNA), TG Therapeutics (TGTX), Indivior (INDV), Janux Therapeutics (JANX), ACADIA Pharmaceuticals (ACAD), Arvinas (ARVN), Bausch Health Companies (BHC), Maravai LifeSciences (MRVI), and Deciphera Pharmaceuticals (DCPH). These companies are all part of the "pharmaceutical preparations" industry.
Albireo Pharma (NASDAQ:ALBO) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment.
AnaptysBio received 53 more outperform votes than Albireo Pharma when rated by MarketBeat users. Likewise, 65.61% of users gave AnaptysBio an outperform vote while only 56.65% of users gave Albireo Pharma an outperform vote.
AnaptysBio has a consensus target price of $46.38, suggesting a potential upside of 93.71%. Given Albireo Pharma's higher probable upside, analysts plainly believe AnaptysBio is more favorable than Albireo Pharma.
Albireo Pharma has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.32, suggesting that its share price is 132% less volatile than the S&P 500.
Albireo Pharma has higher revenue and earnings than AnaptysBio. Albireo Pharma is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.
Albireo Pharma has a net margin of -228.51% compared to Albireo Pharma's net margin of -711.17%. AnaptysBio's return on equity of -97.13% beat Albireo Pharma's return on equity.
In the previous week, AnaptysBio had 6 more articles in the media than Albireo Pharma. MarketBeat recorded 6 mentions for AnaptysBio and 0 mentions for Albireo Pharma. Albireo Pharma's average media sentiment score of 1.03 beat AnaptysBio's score of 0.20 indicating that AnaptysBio is being referred to more favorably in the news media.
94.3% of Albireo Pharma shares are owned by institutional investors. 6.9% of Albireo Pharma shares are owned by company insiders. Comparatively, 33.7% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
AnaptysBio beats Albireo Pharma on 11 of the 17 factors compared between the two stocks.
Get AnaptysBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AnaptysBio Competitors List
Related Companies and Tools
